In a Chinese trial published in JAMA oncology, the addition of adjuvant #capecitabine improved failure-free survival (FFS) among patients with...

In the randomized ALPINE trial, #Zanubrutinib (second-generation BTK inhibitor) improved the outcomes versus #ibrutinib (first-generation BTK inhibitor) in patients with...

In phase III AUGMENT trial presented by Dr. John Leonard at the 2022 American Society of Hematology (ASH) Annual Meeting,...

#Radiation_therapy boost improved local control in DCIS of the breast with one or more risk factors as recently shown by...

An individualized breast cancer risk assessment model for women attending screening in BreastScreen Norway. The large retrospective cohort study included...

In CABASTY trial presented by Dr. Stephane Oudard, #Cabazitaxel 16 mg/m2 every 2 weeks (CBZ q2w) + G-CSF was compared...

In the phase 3 CAPItello-291 trial, presented at the SABCS, the addition of #capivasertib, an oral AKT inhibitor, to fulvestrant...

In the multicentre, randomized CHOICE-01 study, #Toripalimab with chemotherapy was investigated as first-line treatment in treatment-naïve patients with advanced #NSCLC...

In phase III CodeBreak 200 trial presented by Dr. Melissa Johnson, oral #sotorasib demonstrated superior PFS and ORR compared to...

In COSMIC-312 trial, first line #Cabozantinib plus #atezolizumab improved PFS versus #sorafenib for patients with advanced HCC. In this phase...